ClinicalTrials.gg
RecruitingNCT05736419Updated Jun 3, 2026

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

A Phase 2 interventional study of Fludarabine and Cyclophosphamide in Sickle Cell Disease, Thalassemia, Beta and Thalassemia, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 6 sites in United States. Open to participants aged 2 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
2 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing fludarabine in Anemia, Sickle Cell — 4 open to participants now, 8 under way, none of them phase 3. fludarabine · Anemia, Sickle Cell.

Planned enrollment
10th of 22
24 · median 21
Started
2023
the only one that year
Phase 2
12 of 22
3 open now
Registered
22nd of 22
by date
Lead sponsor
1 of 22
Memorial Sloan Kettering Cancer Center

Among the 22 studies testing fludarabine in Anemia, Sickle Cell, this one is the 10th largest by planned enrollment, is the only one that started in 2023, is one of 12 in phase 2, and was the 22nd registered.

Anemia, Sickle Cell

1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

4 of the 22 studies testing fludarabine in Anemia, Sickle Cell are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About fludarabine

fludarabine: first FDA approval 1991 (FLUDARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 2 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing fludarabine in Anemia, Sickle Cell, or all of them as a file.
02

Study summary

Hematopoietic Cell Transplantation/HCT involves receiving healthy blood-forming cells (stem cells) from a donor to replace the diseased or damaged cells in participants' bone marrow. The researchers think giving participants treatment with fludarabine and dexamethasone, drugs that lower the activity of the body's immune system (immune suppression), before standard conditioning therapy and HCT may help prevent serious side effects, including graft failure and GvHD. In this study, depending on how participants' body responds to the fludarabine and dexamethasone, the study doctor may decide participants should receive another drug, called cyclophosphamide, instead of fludarabine. In addition, depending on the results of participants' routine blood tests, participants may receive the drugs bortezomib and rituximab, which also help with immune suppression.

03

Conditions studied

  • Sickle Cell Disease
  • Thalassemia, Beta
  • Thalassemia

Keywords

  • allogeneic hematopoietic cell transplantation
  • Sickle Cell Disease
  • Beta Thalassemia
  • Thalassemia
  • 23-009
  • Memorial Sloan Kettering Cancer Center
04

Who can participate

Ages eligible
2 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 2 and ≤ 50 years
  • Suitable haploidentical donor.
  • Performance score ≥ 70% by Performance Scale or 0 to 1 by (age > 16 years), or Lansky Play-Performance Scale ≥ 70% (age ≤ 16 years).
  • Adequate major organ system function as demonstrated by:

    • For patients ≥ 18 years of age:
    • ≥ 50 mL/min by formula Formula: ((140 - Age) x Weight (kg)) / (72 x Serum Creatinine (mg/dL) Female Adjustment: Multiply result by 0.85
    • For patients \< 18 years of age:
    • Serum creatinine clearance: glomerular filtration rate [GFR]) must be >50 mL/min/1.73 m2 as calculated by the Schwartz formula
  • Conjugated (direct) less than 3x .
  • or AST ≤ 3 times institutional upper limit of normal.
  • ≥ 50%.
  • Diffusing capacity for carbon monoxide (DLCO) ≥ 50% predicted, corrected for . For children \< 7 years of age who are unable to perform PFT, oxygen saturation > 92% on room air by pulse oximetry.
  • For SCD patients: HbSS, HbSC, HbS/β° with one or more of the following complications:

    • Acute chest syndrome: 2 or more episodes in the 2 years preceding enrollment
    • Vaso-occlusive episodes: 3 or more episodes in the 2 years preceding enrollment
    • Recurrent priapism: 2 or more episodes in the 2 years preceding enrollment
    • History of osteomyelitis or osteonecrosis
    • Cerebrovascular disease:
  • Imaging evidence of prior overt or silent stroke
  • History of a neurologic event resulting in focal neurologic deficits lasting > 24 hours
  • Abnormal transcranial Doppler: Timed average maximum mean velocity ≥ 200 cm/sec in terminal portion of the carotid or proximal portion of the middle cerebral artery or > 185 cm/sec plus evidence of intracranial vasculopathy if imaging TCD is used

    • Pulmonary hypertension: Confirmed by right heart catheterization with mean pulmonary arterial pressure ≥ 25 mmHg or mean pulmonary vascular resistance > 2 Wood units
    • Red blood cell alloimmunization (> 3 alloantibodies)
  • For thalassemia patients: Any genotype, with all of the following:

    • Onset of red blood cell transfusion dependence during the first 3 years of life
    • RBC transfusion history > 225 mL/kg/year or > 15 lifetime RBC transfusions
    • Pre-transfusion hemoglobin ≤ 7 g/dL
    • Hepatosplenomegaly
  • Patient or the patient's legal representative, parent(s) or guardian should be able to provide written . Assent of a minor if participant's age is at least seven and less than eighteen years.
  • For sexually active men and women of , must agree to use a form of considered effective and medically acceptable by the Investigator.

Exclusion criteria

Exclusion Criteria:

  • Prior myeloablative HCT.
  • Overt stroke or CNS instrumentation (e.g. for Moyamoya disease) within 6 months of enrollment.
  • Liver cirrhosis. Mild fibrosis will be permitted, i.e. fine reticulin or grade 1 of 4, with bridging fibrosis.
  • Hepatic iron content ≥ 3 mg Fe/g liver dry weight, if applicable
  • Active or C.
  • Other uncontrolled infections.
  • Other /cancer diagnosis unless in remission after definitive therapy for a minimum of 2 years. Exceptions: Ductal carcinoma in situ, basal cell carcinoma, cervical intraepithelial neoplasia.
  • Positive pregnancy test in a woman with , defined as not for 12 months or no previous surgical sterilization.
  • Inability to comply with medical therapy or follow-up.
  • Known history of allergic reactions to any constituents of the stem cell product, including a known history of allergic reactions to DMSO.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Participants with Sickle Cell Disease or β-Thalassemia

    Participants will have severe sickle cell disease or transfusion-dependent β-thalassemia.

    Drug: Fludarabine · Drug: Cyclophosphamide · Drug: Tacrolimus · Drug: Mycophenolate Mofetil · Biological: Rabbit ATG · Drug: Dexamethasone · Drug: Bortezomib · Drug: Rituximab

Interventions

  • PK-guided fludarabine dosing will be used for each of the 2 cycles, using the InsightRx DoseMeRx platform.

  • Cyclophosphamide will be administered Post-Transplant

  • Tacrolimus will be administered beginning on day +5

  • DrugMycophenolic AcidStudies of Mycophenolic AcidMycophenolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Mycophenolate mofetil (MMF) will be administered three times daily starting on day +5.

  • BiologicalThymoglobulinStudies of ThymoglobulinThymoglobulin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The dose and schedule of ATG will be determined according to the nomogram in Appendix A

  • Standard Regimen: Dexamethasone on days -68 to -64 and days -40 to -36.

  • Bortezomib on days -71, -68, -65, -61, -43, -40, -37, and -33

  • Rituximab on days -71, -58, -43, and -30.

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment related mortality/TRM or primary graft failure

    The primary outcome is to estimate treatment-related mortality (TRM) or primary graft failure at 1 year post-HCT.

    Time frame: 1 year

07

Study locations

6 of 6 sites recruiting
  • Memorial Sloan Kettering at Basking Ridge (Consent only)
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Maria Cancio, MD · Contact212-639-2446
  • Memorial Sloan Kettering Monmouth (Consent only)
    Middletown, New Jersey 07748, United States
    Recruiting
    • Maria Cancio, MD · Contact212-639-2446
  • Memorial Sloan Kettering Bergen (Consent only)
    Montvale, New Jersey 07645, United States
    Recruiting
    • Maria Cancio, MD · Contact212-639-2446
  • Memorial Sloan Kettering Suffolk - Commack (Consent only)
    Commack, New York 11725, United States
    Recruiting
    • Maria Cancio, MD · Contact212-639-2446
  • Memorial Sloan Kettering Westchester (Consent only)
    Harrison, New York 10604, United States
    Recruiting
    • Maria Cancio, MD · Contact212-639-2446
  • Memorial Sloan Kettering Nassau (All protocol activities)
    Rockville Centre, New York 11553, United States
    Recruiting
    • Maria Cancio, MD · Contact212-639-2446
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Feb 2027, 48 months after the start.

Of 59 non-industry phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 117. This study's planned 48 months is below that.

Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2023
First posted
Feb 21, 2023
StartActual
Feb 9, 2023
Primary completionEst.
Feb 9, 2027
CompletionEst.
Feb 9, 2027
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05736419
Responsible party
Sponsor
First posted
Feb 21, 2023
Start date
Feb 9, 2023
Primary completion
Feb 9, 2027 (estimated)
Completion
Feb 9, 2027 (estimated)
Last update
Jun 3, 2026

Study contacts

Maria Cancio, MD
Contact
canciom@mskcc.org
212-639-2446
Jaap Jan Boelens, MD, PhD
Contact
boelensj@mskcc.org
212-639-3643
Maria Cancio, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fludarabine · Cyclophosphamide · Tacrolimus · Mycophenolic Acid · Thymoglobulin · Dexamethasone · Bortezomib · Rituximab

Start the discussion